TREATMENT'OUTCOMES'OF'ADVANCED'STAGE'HODGKIN'LYMPHOMA:'
POSTER'31'
SINGLE'CENTER'TUNISIAN'EXPERIENCE'
'
Raoudha!Mansouri1,! Karima! Kacem1,! Dorra! Jabr1,! Tarek! Ben! Ahmed2,! Rimel! Kanoun1,!Manel! Bchir1,!
Salma! Kefi1,! Emna! Barred1,! Meriem! Achour1,! Marwa! Bahri1,! Rachid! Kharrat1,! Yosr! Ben! Abdennebi1,!
Hend!Ben!Neji1,!Raihane!Ben!Lakhal1,!Lamia!Aissaoui1and!Balkis!Meddeb1!
!
(1)Aziza!Othmana!Hospital,!TUNIS,!Tunisia,!(2)Farhad!Hached!Hospital,!Sousse,!Tunisia!
!
Introduction:!
The!extended!stage!is!a!prognostic!factor!for!Hodgkin!lymphoma!(HL).!The!treatment!of!HL!
extended!stage,!in!Tunisia,!is!done!according!the!national!protocol!(MDH2015)!which!consist!
of! escJBEACOPP! for! young! patients! (≤60! years)! with! early! assessment! (after! two! courses).!
For!elderly!patients!(>60!years)!the!treatment!depend!on!the!presence!of!comorbidities.!In!
this!work,!we!propose!to!evaluate!the!therapeutic!response!(after!2!courses!and!at!the!end!
of! treatment)! and! to! analyze! the! survivals! (SSE! eventJfree! survival,! OS! overall! survival! and!
SSR! relapseJfree! survival! of! patients! with! extended! stage! HL! and! treated! according! to! the!
Tunisian!protocol.!
Patients'and'methods:!
Our! prospective! study! had! included! 105! patients! with! extended! stage! LH,! followed! in! the!
clinical! hematology! department! of! the! Aziza! Othmana! hospital! between! January! 2015! and!
December! 2018! and! treated! according! MDH15! protocol.! Patients! under! 60! years! with!
extended! stage! (localized! stage! with! large! mediastinal! mass,! Ann! Arbor! stage! III! and! IV)!
treated! with! 6! courses! escJBEACOPP! or! 2! courses! escJBEACOPP! and! 4! courses! ABVD!
depending! on! the! response! to! 2! courses.! Patients! over! 60! years! old! are! treated! by,!
respectively,!AVD!+/J!RT!and!COPP!cures!according!to!the!comorbidities.!Primary!failure!is!
defined! as! a! response! <75%! to! 4! courses! of! chemotherapy! or! positive! PET! (SD>!
3).Caractéristiques)des)patients:)The!median!age!is!31!years!15J88!years!with!a!sex!ratio!of!
1.26.! SixtyJfive! percent! (65%)! of! our! patients! had! B! signs.! A! large! mediastinal! mass!
(MTI≥0.35)! was! noted! in! 28%.! Bulky! mass! was! noted! in! 24%! of! patients.! ISP≥3! is! found! in!
53%!of!patients.'Results':!90!patients!were!evaluable!at!the!time!of!the!interim!evaluation:!
the!early!response!to!2!courses!(≥!75%)!is!44%!response.!This!response!was!84%!at!the!end!
of!treatment!(59%!CR)!and!16%!primary!failure!was!observed.!The!median!followJup!was!32!
months!8J52!months.!Six!relapses!occurred!within!a!median!of!2!months!2J6!months.!The!
5Jyear!RFS!was!96%.!The!5Jyear!EFS!was!85%.!OS!at!5!years!was!89%.!
Conclusion:!
The!rate!of!primary!failure!in!extensive!stages!of!HL!remains!relatively!high,!requiring!more!
intensive!treatment!and!more!precise!assessment,!including!TEP!
! !
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES